GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BSF Enterprise PLC (LSE:BSFA) » Definitions » Common Stock

BSF Enterprise (LSE:BSFA) Common Stock : £1.03 Mil (As of Sep. 2024)


View and export this data going back to 2019. Start your Free Trial

What is BSF Enterprise Common Stock?

BSF Enterprise's quarterly common stock stayed the same from Sep. 2023 (£1.03 Mil) to Mar. 2024 (£1.03 Mil) and stayed the same from Mar. 2024 (£1.03 Mil) to Sep. 2024 (£1.03 Mil).

BSF Enterprise's annual common stock increased from Sep. 2022 (£0.86 Mil) to Sep. 2023 (£1.03 Mil) but then stayed the same from Sep. 2023 (£1.03 Mil) to Sep. 2024 (£1.03 Mil).


BSF Enterprise Common Stock Historical Data

The historical data trend for BSF Enterprise's Common Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BSF Enterprise Common Stock Chart

BSF Enterprise Annual Data
Trend Sep19 Sep20 Sep21 Sep22 Sep23 Sep24
Common Stock
Get a 7-Day Free Trial 0.20 0.20 0.86 1.03 1.03

BSF Enterprise Semi-Annual Data
Mar19 Sep19 Mar20 Sep20 Mar21 Sep21 Mar22 Sep22 Mar23 Sep23 Mar24 Sep24
Common Stock Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.86 1.03 1.03 1.03 1.03

BSF Enterprise Common Stock Calculation

Common stock is listed on the Balance Sheet at the par value of the total shares outstanding of a company.

The par value of common stocks is meaningless. It is usually set at an absurdly low number.


BSF Enterprise Business Description

Traded in Other Exchanges
Address
2 Portman Street, London, GBR, W1H 6DU
BSF Enterprise PLC is a United Kingdom-based biotech company. The Company is focused on developing biotechnological solutions using cell-based tissue engineering to help generate cultured meat, lab-grown leather, as well as human corneas, collagen growth and skin substitutes. The Company operates through its wholly owned subsidiary, 3D Bio-Tissues Limited (3DBT), which is a clinical and cellular agriculture company engaged in producing human corneas that could help restore vision to millions of people.

BSF Enterprise Headlines

No Headlines